Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Queensland Health
Cerilliant
Medtronic
Baxter
Fish and Richardson
Healthtrust

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NELARABINE

« Back to Dashboard

Clinical Trials for Nelarabine

Trial ID Title Status Sponsor Phase Summary
NCT00002970 506U78 in Treating Patients With Refractory Hematologic Cancer Completed Children's Cancer Group Phase 2 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 506U78 in Treating Patients With Refractory Hematologic Cancer Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003545 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed Southwest Oncology Group Phase 2 Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
NCT00003545 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nelarabine

Condition Name

Condition Name for Nelarabine
Intervention Trials
Leukemia 7
Lymphoblastic Lymphoma 4
Acute Lymphoblastic Leukemia 3
Untreated Childhood Acute Lymphoblastic Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nelarabine
Intervention Trials
Leukemia 17
Precursor Cell Lymphoblastic Leukemia-Lymphoma 17
Leukemia, Lymphoid 16
Lymphoma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nelarabine

Trials by Country

Trials by Country for Nelarabine
Location Trials
United States 159
Germany 12
Canada 11
Australia 7
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nelarabine
Location Trials
Texas 9
California 8
Ohio 6
Missouri 6
Illinois 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nelarabine

Clinical Trial Phase

Clinical Trial Phase for Nelarabine
Clinical Trial Phase Trials
Phase 3 4
Phase 2 12
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nelarabine
Clinical Trial Phase Trials
Completed 10
Recruiting 5
Active, not recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nelarabine

Sponsor Name

Sponsor Name for Nelarabine
Sponsor Trials
National Cancer Institute (NCI) 10
GlaxoSmithKline 6
Novartis 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nelarabine
Sponsor Trials
Other 14
Industry 11
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Chinese Patent Office
Accenture
Argus Health
Johnson and Johnson
AstraZeneca
Healthtrust
Cantor Fitzgerald
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.